Lipum
13.40 SEK
-4.29 %
Less than 1K followers
LIPUM
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-4.29 %
-2.90 %
-8.22 %
-8.53 %
-9.15 %
-19.28 %
+16.96 %
-
-38.73 %
Lipum is a biopharmaceutical company. The company is in clinical phase and specializes in the discovery and development of new treatments for chronic inflammatory diseases. The company's drug candidate is based on an antibody that is intended to be used in treatments to block a specific molecule in the immune system. The drug candidate is in clinical phase with preclinical data for rheumatism. The company is also evaluating other diseases. Lipum has its operations in Umeå.
Read moreMarket cap
284.25M SEK
Turnover
68.87M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28/4
2026
Interim report Q1'26
12/5
2026
General meeting '26
27/8
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
The Swedish Companies Registration Office has granted permission to implement the merger plan between Flerie and Lipum
Lipum utvalt för Horizon Europe bidrag
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools